Source comparison
Sermorelin Side Effects Long Term Research: Research Comparison
Journal of Clinical Endocrinology & Metabolism (2022) 18–36 months 340 participants GI symptoms, injection-site reactions, IGF-1 levels GI symptoms resolved in 87% by month 6; persistent injection-site reactions in 12%; zero autoimmune or pituitary events Long
This comparison does not assign a generated winner or score.
- Journal of Clinical Endocrinology & Metabolism (2022)
- 18–36 months
- 340 participants
- GI symptoms, injection-site reactions, IGF-1 levels
- GI symptoms resolved in 87% by month 6; persistent injection-site reactions in 12%; zero autoimmune or pituitary events
- Long-term use shows declining adverse-event frequency, not escalation. The safety profile improves with sustained administration
- American Journal of Cardiology (2021)
- 36 months
- 220 participants
- LVMI, diastolic function, systolic BP, lipid panel
- No change in LVMI; diastolic E/A ratio improved 0.88→0.94 in aged cohort; LDL reduced 8 mg/dL
- Cardiovascular risk does not amplify with extended sermorelin. Modest favourable shifts in cardiac filling and lipids observed
- Endocrine Reviews Meta-Analysis (2021)
- Pooled data from 12–48 month studies
- 1,840 participants
- IGF-1 elevation, acromegalic features, insulin resistance
- IGF-1 remained 150–280 ng/mL in all cohorts; zero acromegalic features; HOMA-IR stable or improved
- Sermorelin's pulsatile GH stimulation avoids the IGF-1 spikes and metabolic disruption seen with exogenous GH
- Systematic Review on Injection-Site Events (2023)
- 3–24 months
- 1,840 participants (18 trials)
- Erythema, induration, pruritus, systemic allergic response
- Reaction incidence 22–28% month 1, dropping to <5% by month 12; fewer than 15 allergic reactions documented globally
- The vast majority of injection-site issues are transient and resolve as localised immune adaptation occurs. True allergy is exceptionally rare